G207 is a multimutated, conditionally replicating herpes simplex virus type 1 (HSV-1) that retains an intact viral thymidine kinase (HSV-tk) gene. The virus exhibits oncolytic activity in various tumors and is being evaluated in patients with recurrent malignant glioma. In view of the potential for ganciclovir (GCV) to either enhance or inhibit the antitumoral activity of HSV-tk-retaining HSV-1 vectors, we evaluated the effect of GCV administration on the antitumoral activity of G207. In culture, addition of GCV either had no effect or inhibited the cytocidal action of G207 at replication-permissive temperatures, while it significantly increased the cell killing in three of the four cell lines studied when virus replication was inhibited at nonpermissive temperatures. Using a G207-permissive immunocompetent mouse tumor model, subcutaneous N18 neuroblastoma in syngeneic A/J mice, we found that GCV treatment did not affect G207-mediated tumor growth inhibition at a variety of viral doses (10 5 , 10 7 , and 10 7 ϫ 2 plaque-forming units). In A/J mice harboring intracerebral N18 tumors, GCV administration had no significant effect on the prolongation of survival by G207 inoculation. These findings suggest that GCV administration may not be beneficial to the efficacy of G207 tumor therapy under conditions that favor active viral replication, because the potential HSV-tk/GCV-mediated enhancement of G207 oncolytic activity may be balanced out by the inhibitory action of GCV on viral replication. Cancer Gene Therapy ( 1,2 Gliomas account for 40 -67% of the primary brain tumors, and approximately three-fourths of gliomas are considered malignant. Secondary brain tumors due to metastatic malignancy are also common, and the frequency is increasing because of longer survival of cancer patients in general. Despite progress in microsurgical techniques and adjuvant chemotherapy and radiotherapy, little improvement has been noted in the survival rate of patients with malignant brain tumors. The use of herpes simplex virus thymidine kinase (HSVtk) gene transduction using replication-defective vectors followed by ganciclovir (GCV) administration is a therapeutic design that has been extensively studied in brain tumors.
B
rain tumors represent 9% of all primary tumors and are the second leading cause of death from neurological disease. 1, 2 Gliomas account for 40 -67% of the primary brain tumors, and approximately three-fourths of gliomas are considered malignant. Secondary brain tumors due to metastatic malignancy are also common, and the frequency is increasing because of longer survival of cancer patients in general. Despite progress in microsurgical techniques and adjuvant chemotherapy and radiotherapy, little improvement has been noted in the survival rate of patients with malignant brain tumors. The use of herpes simplex virus thymidine kinase (HSVtk) gene transduction using replication-defective vectors followed by ganciclovir (GCV) administration is a therapeutic design that has been extensively studied in brain tumors. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] GCV, a nucleoside analog, is phosphorylated by HSV-tk, but not by endogenous mammalian tk, and is further anabolized by cellular kinases to GCV triphosphate, which inhibits host cell DNA replication by chain termination. 15 An important, advantageous feature of this strategy is that surrounding nontransduced cells can be killed in the presence of GCV in addition to the cells transduced with HSV-tk gene. 3, 7, 16 In vitro studies have shown that this so-called bystander effect is associated with gap junctional intercellular communication, through which phosphorylated GCV is transferred. [17] [18] [19] [20] [21] [22] [23] However, an immune response has been suggested to play a major role in the bystander effect observed in vivo. 6,24 -28 Despite the bystander effect, it has been shown that at least 10% of tumor cells need to be transduced to achieve significant tumor cell kills; 3, 5, 7, 23 therefore, the poor efficiency of replicationdefective vectors to deliver genes in vivo limits the efficacy of this therapy. 11, 29 Replication-competent virus vectors are an attractive means of tumor therapy in that the virus vector can replicate in situ and spread, and, at the same time, exhibit a direct cytopathic effect. In addition, replicationcompetent virus vectors are capable of transferring and expressing foreign genes in host cells. Most of these vectors (HSV-1, adenovirus) are genetically engineered viruses that are intended to restrict viral replication to transformed cells, 30 -36 while others (reovirus) are naturally nonpathogenic in normal human tissues. 37 Recombinant HSV-1 is capable of infecting many cell types, antiviral drugs are available, the genes necessary for neuropathogenicity have been identified and can be deleted or inactivated, and the large size of the viral genome (150 kb) allows insertion of large sequences or multiple genes. G207 is a second-generation, conditionally replicating, recombinant HSV-1 that was initially designed for clinical use in malignant brain tumor patients. 38 It has deletions in both copies of the ␥34.5 gene, which is a gene associated with neurovirulence.
39
G207 also has an insertion of the Escherichia coli lacZ gene in the ICP6 gene (UL39), inactivating ribonucleotide reductase, a key enzyme for viral DNA synthesis in nondividing cells but not in dividing cells. 40, 41 This double mutation minimizes the chance of G207 reverting to wild-type and confers favorable properties on the virus for treating human brain tumors: preferential replication in tumor cells, attenuated neurovirulence, GCV/acyclovir hypersensitivity, and the presence of an easily detectable histochemical marker (lacZ). G207 has been shown to effectively kill multiple types of human malignant tumor cells in culture and in nude mice harboring tumors subcutaneously (s.c.) or intracranially 38, 42, 43 and has been shown to be significantly less toxic than wild-type HSV-1 when injected into the brains of mice or non-human primates.
38
G207 is currently in a clinical trial for patients with recurrent malignant glioma. 44 One unanswered question is the effect of GCV on the therapy. G207 retains an intact HSV-tk gene and exhibits a higher sensitivity to GCV than the parent virus, R3616, or wild-type HSV-1. 38 Therefore, conflicting aspects of the effect of GCV must be considered: Administration of GCV may induce the death of not only G207-infected tumor cells but also of noninfected cells by the "bystander" effect, thereby enhancing the antitumoral efficacy of G207. GCV-mediated cell death may also elicit a stronger immune response against tumor cells. However, inhibition of G207 replication by GCV could prevent the further spread and oncolytic activity of G207; therefore, the antitumoral action could be diminished. It has been reported that GCV administration in the 9L rat gliosarcoma brain tumor model significantly increased the antitumoral action of hrR3, a replication-competent, ICP6-inactivated mutant HSV-1 that retains an intact HSV-tk gene. 45, 46 However, this enhancement has not been reproducible with other tumor types 12, 47, 48 or other HSV-1 vectors; 12, 36 therefore, whether GCV administration is beneficial to replication-competent HSV-1 tumor therapy remains controversial. One difficulty in investigating the efficacy of recombinant HSV-1 tumor therapy in vivo has been the lack of an appropriate animal tumor model, because many mouse strains and murine cell lines are resistant to HSV-1 infection. 49 We have recently used N18 murine neuroblastoma cells that are moderately susceptible to G207 and reproducibly form s.c. or intracerebral tumors in syngeneic A/J mice. 50, 51 This immunocompetent mouse tumor model has proven suitable for testing of the therapeutic efficacy of recombinant HSV-1. In this study, we evaluate the effect of GCV on G207 tumor therapy in vitro using several different cell lines and in vivo using the N18 mouse tumor model. We demonstrate that a GCV-mediated enhancement of the cytopathic effect in cell culture is observed only when the replication of G207 was inhibited by a nonpermissive temperature. We further demonstrate that GCV administration does not increase the antitumoral efficacy of G207 in immunocompetent mice bearing tumors in the brain or skin, but rather allows delayed regrowth of tumors.
MATERIALS AND METHODS

Cell lines and viruses
The N18 cell line is a subclone of C1300 murine neuroblastoma cells derived from an A/J mouse (H-2 a ), 52 and was kindly provided by Dr. Kazuhiko Ikeda (Tokyo Institute of Psychiatry, Tokyo, Japan). Vero (African green monkey kidney) cells and U87MG human glioblastoma cells were obtained from the American Type Culture Collection (Manassas, Va). F5 human malignant meningioma cells were provided by Dr. Anil G. Menon (University of Cincinnati, Cincinnati, Ohio). These cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf sera, 2 mM glutamine, penicillin (100 U/mL), streptomycin (100 g/mL), and 2.5 g/mL Fungizone. Stocks of G207 were grown in Vero cell cultures, and virus titers were determined as described previously. 53 In vitro cytotoxicity studies Cells were plated in 6-well plates at 1-4 ϫ 10 5 cells/well. After a 24-hour incubation at 37°C, cells were infected with G207 at a multiplicity of infection (MOI) of 0.1 or with virus buffer (150 mM NaCl, 20 mM tris(hydroxymethyl)aminomethane (pH 7.5)) and further incubated at 37°C. At 8 hours (Vero), 24 hours (F5), or 48 hours (U87MG and N18) postinfection, cells were treated with or without GCV at a concentration of 1 g/mL and further incubated at either 34.5°C or 39.5°C. Before, 2 days after, and 5 days after GCV treatment, three wells for each treatment group were used to count the number of surviving cells. Cells were washed twice with 1 mL of phosphate-buffered saline to eliminate floating cells, trypsinized, and counted using a Coulter counter (Coulter, Luton, Bedfordshire, UK). The cytopathic effect of G207 was determined as the decreased number of surviving cells compared with mock-infected controls. At the time of GCV administration, 20 -30% of cells exhibited a cytopathic effect in the latter three cell lines. 38, 42, 50 It has been confirmed in multiple experiments that the data from Coulter counter coincide with the viable cell counts obtained with a hemocytometer using a trypan blue dye exclusion method.
Animal studies
Six-week-old female A/J mice were purchased from the National Cancer Institute (Frederick, Md) and caged in groups of four or less. For injections and surgical procedures, each mouse was anesthetized with an intraperitoneal (i.p.) injection of a 0.20-to 0.25-mL solution consisting of 86% saline, 9% sodium pentobarbital, and 5% ethyl alcohol. All animal procedures were approved by the Georgetown University Animal Care and Use Committee.
female A/J mice. N18 cells have been shown to be moderately immunogenic in A/J mice. 50 When s.c. tumors reached ϳ6 mm in diameter, 20 L of G207 (1 ϫ 10 7 plaque-forming units (PFU) or 1 ϫ 10 5 PFU) or mock-infected extract was inoculated intraneoplastically into the tumor (day 0). Mock-infected extract was prepared from virus buffer-infected cells using the same procedures as those used for virus inoculum. In one experiment, the treatment was repeated on day 3. In addition, 0.1 mL of GCV (50 mg/kg) or saline was administered by i.p. injection once a day for 7 consecutive days starting at day 7. Tumor growth was determined by measuring the tumor volume (length ϫ width ϫ height) twice a week. The body temperature of A/J mice ranges from 36.5°C to 38°C, 54 within the range of permissive temperatures for G207 replication. The animals were sacrificed by i.p. injection of sodium pentobarbital when the s.c. tumors reached 24 mm in maximal diameter or when ulceration occurred. Statistical significance of the differences in mean tumor volume was assessed by an unpaired Student's t test.
Intracerebral tumor therapy
Intracerebral tumors were generated by injecting 5 ϫ 10 5 N18 cells in 5 L of serum-free medium stereotactically into the right frontal lobe of A/J mice. After 5 days, 5 L of G207 (1.5 ϫ 10 7 PFU) or mock-infected extract was inoculated stereotactically at the same coordinates. At 3 days postinoculation, 0.1 mL of GCV (50 mg/kg) or saline was administered by i.p. injection once a day for 7 consecutive days, and survival was followed. Statistical significance of the difference in survival was assessed by the Wilcoxon test.
Rechallenge studies
Animals whose s.c. tumors had been cured by either G207 plus saline treatment or G207 plus GCV treatment were rechallenged with a s.c. injection of 5 ϫ 10 6 N18 cells in 50 L of serum-free medium into the right flank region, and tumor growth was determined as described above. Three-month-old naive female A/J mice were used as controls.
RESULTS
GCV effect on G207 cytotoxicity in vitro Four cell lines with different characteristics were used to investigate the effect of GCV on G207-mediated cytotoxicity in vitro. Vero cells are highly susceptible to HSV in general. U87MG and F5 cells are human malignant brain tumor lines that have been used previously to study the oncolytic effect of G207 extensively both in vitro and in vivo; 38, 42 F5 cells are more susceptible to G207 than U87MG cells. The N18 cell line, which is a clone derived from C1300 murine neuroblastoma cells, is less susceptible to G207 than these three primate cell lines, although it is one of the most susceptible murine cell lines we have examined.
50 C1300-derived cells are prone to HSV-tk/GCV-mediated cell killing. 21, 55 The status of gap junction has not been identified for the investigated cell lines except for U87MG cells, which have been shown to express intermediate mRNA and protein levels of connexin43. 20, 25 Morphologically, Vero cells show high cell-to-cell contact, U87MG and F5 cells show intermediate cell-to-cell, and N18 cells show minimal cell-to-cell contract. The cells were infected with G207 (MOI of 0.1) or phosphate-buffered saline and treated with or without GCV (1 g/mL) for 2 days; next, the surviving cells were counted. It was intended that, at the time of GCV administration, the direct killing by the virus would not exceed 30% of the cells, to be able to observe the additional effect of GCV. When the cells were incubated at 34.5°C (a permissive temperature for G207 replication), the addition of GCV resulted in decreased G207-mediated cytotoxicity in Vero and U87MG cells, increasing the number of surviving cells by 23% and 38%, respectively, compared with G207 alone (P Ͻ .01 and P Ͻ .05, respectively; unpaired Student's t test; Fig 1A) . GCV had no significant effect on G207-mediated cytotoxicity in F5 and N18 cells at this temperature. On the contrary, when the cells were incubated at 39.5°C (an inhibitory temperature for G207 replication), GCV administration enhanced the cytopathic effect of G207 in all cell lines tested except for N18 ( Fig  1B) . GCV in addition to G207 resulted in a 42%, 20%, and 40% decrease in surviving cell number for Vero, F5, and U87MG cells, respectively, compared with G207 alone (P Ͻ .001, P Ͻ .05, and P Ͻ .01, respectively; unpaired Student's t test). When cells were counted 5 days after GCV treatment, results showed similar tendency for all experiments (data not shown).
GCV effect on G207 s.c. tumor therapy
Accumulating evidence suggests that an immune response plays a central role in the HSV-tk-mediated bystander effect.
6,24 -28 Therefore, we used an immunocompetent animal model to evaluate the in vivo effect of GCV on G207 antitumoral activity. A/J mice harboring s.c. N18 tumors were treated with a single intraneoplastic inoculation of G207 (1 ϫ 10 7 PFU) or mock-infected extract. GCV was administered for 7 consecutive days starting at day 7, similarly to the initial protocol described by Boviatsis et al. 45 It has been demonstrated that a significant amount of G207 replication is still occurring at 7 days postinfection in s.c. N18 tumors, as evidenced by titration of recovered infectious G207 and 5-bromo-4-chloro-3-indolyl ␤-D-galactoside histochemistry. 50, 56 G207 treatment resulted in a significant suppression of tumor growth regardless of whether or not GCV was administered; four of six and five of six animals showed a Ͼ75% reduction in tumor size (responders) for the G207 plus saline and G207 plus GCV groups, respectively (Fig 2A) . The mean tumor volumes (Ϯ SEM) of the mock plus saline, mock plus GCV, G207 plus saline, and G207 plus GCV groups at day 14 postinoculation were 4586 (Ϯ 886), 4217 (Ϯ 465), 1481 (Ϯ 1130), and 779 (Ϯ 692) mm 3 , respectively. There was no significant difference in the mean tumor volume between the two mock groups and between the two G207 groups at any timepoint (unpaired Student's t test). However, two responders in the G207 plus GCV group exhibited regrowth of tumors after termination of the GCV administration, whereas all four responders in the G207 plus saline group remained cured for 300 days until the study was terminated.
To examine the effect of GCV on multiple, high-dose inoculations of G207, A/J mice with established s.c. N18 tumors were given an intraneoplastic inoculation of G207 (1 ϫ 10 7 PFU) on days 0 and 3. GCV administration starting at day 7 (4 days after the second virus inoculation) caused no difference in the oncolytic activity exhibited by G207 (Fig 2B) . In both the G207 plus saline and G207 plus GCV groups, five of six animals remained cured for 120 days until the study was terminated. The result also implies that an early administration of GCV does not alter the outcome.
To further examine the GCV effect on low-dose inoculations of G207, a single inoculation of G207 (1 ϫ 10 5 PFU) was given intraneoplastically to s.c. N18 tumor-bearing A/J mice. This dose was sufficient to cause a significant suppression of tumor growth ( Fig  2C) . Again, GCV administration did not affect G207 efficacy. The mean tumor volumes (Ϯ SEM) of the four Figure 1 . Effect of GCV administration on the cytotoxic activity of G207 in vitro. At 8 hours (Vero), 24 hours (F5), or 48 hours (U87MG and N18) after infection with G207 (MOI of 0.1) or virus buffer, cells were treated with or without GCV (1 g/mL) and incubated at either 34.5°C (A) or 39.5°C (B) for 2 days; next, the number of surviving cells was counted. An enhancement of G207 cytotoxicity with GCV was observed only when virus replication was inhibited by incubation at a nonpermissive temperature (39.5°C). Results are the mean of triplicate determinations Ϯ SD. ‫,ء‬ P Ͻ .05; ‫,ءء‬ P Ͻ .01; ‫,ءءء‬ P Ͻ .001; unpaired Student's t test. treatment groups at day 24 postinoculation were 8071 (Ϯ 2209), 7844 (Ϯ 1303), 1576 (Ϯ 1142), and 2786 (Ϯ 1181) mm 3 , respectively. There was no significant difference in the mean tumor volume between the two mock groups and between the two G207 groups at any timepoint (unpaired Student's t test). In both the G207 plus saline and G207 plus GCV groups, three of six animals remained cured for 60 days after inoculation until the study was terminated.
To test whether GCV administration affects the antitumoral immunity induced by G207 tumor therapy, 50, 57 the mice cured by the G207 s.c. tumor therapy with or without GCV were rechallenged with a s.c. injection of N18 cells. All 10 naive, 3-month-old A/J mice exhibited palpable tumors that either grew continuously or subsequently regressed. In contrast, all of the mice in the G207 plus saline group (n ϭ 12) and in the G207 plus GCV group (n ϭ 8) rejected the rechallenge without any sign of tumor growth.
GCV effect on G207 intracerebral tumor therapy A/J mice harboring intracerebral N18 tumors were used to investigate the effect of GCV on the treatment of brain tumors with G207. All mice inoculated with mockinfected extract with or without GCV administration died from brain tumor formation within 18 days of tumor implantation, although GCV administration caused a short prolongation of survival (P ϭ 0.003, Wilcoxon test; Fig 3) . A single inoculation of G207 (1.5 ϫ 10 7 PFU) significantly prolonged the survival of these animals regardless of whether or not GCV was administered for 7 days (P Ͻ .01, mock plus saline or mock plus GCV versus G207 plus saline or G207 plus GCV, Wilcoxon test). No significant difference in survival was observed between the G207 plus saline and the G207 plus GCV groups.
DISCUSSION
It is difficult to evaluate the effect of GCV in combination with replication-competent HSV-1. Many variables can influence the effect in vitro, such as susceptibility to the virus; cell-to-cell contact and the presence of gap junctions; the number of cells plated; the timing, amount, and duration of GCV administration; viral replication; and the sensitivity of the virus to GCV. At a nonpermissive temperature for G207 replication (39.5°C), addition of GCV increased cell killing in three of the four cell lines tested, suggesting a bystander effect. PFU on day 0 only (C). GCV (50 mg/kg) or saline was administered daily by i.p. injection for 7 consecutive days starting at day 7. The tumor volume (length ϫ width ϫ height) of individual animals is depicted. GCV administration caused no significant difference in the mean tumor volume of G207-treated animals at any G207 dosage.
The nonpermissive temperature inhibits replication and the direct cytopathic action of G207; hence, the effect of HSV-tk-mediated cell killing may be detected. In contrast, at a permissive temperature at which the virus replicates and spreads actively, the benefit of the limited HSV-tk-mediated cytotoxicity by GCV administration may not exceed the disadvantage of inhibiting the replication of the virus. In fact, at the permissive temperature (34.5°C), addition of GCV inhibited the cytotoxicity in two of the four cell lines studied. Because it has been demonstrated repeatedly that an immune response plays a central role in the HSV-tk/ GCV-mediated bystander effect, 6,24 -28 it was important to seek an immunocompetent animal model for in vivo evaluations. Although U87MG cells have been shown to manifest bystander cell killing in vitro, the effect has not been demonstrable in vivo using nude mice. 25 A difficulty in evaluating the efficacy of replication-competent HSV-1 in vivo has been the lack of suitable immunocompetent animal tumor models due to the relative resistance of rodent cells to HSV-1 infection. The 9L rat gliosarcoma model has been used for replication-competent HSV studies 36, 45, 46 as well as HSV-tk/GCV therapy, [5] [6] [7] 10, 11, 14 but the cell line is highly resistant to HSV-1, 36 especially G207 (our unpublished data), and is immunogenic; 58 therefore, it is not suitable for G207 studies. A/J is one of the most sensitive mouse strains to HSV-1 infection, 49 and syngeneic N18 tumors in A/J mice are very responsive to G207 treatment. 50, 51 G207-mediated oncolysis in N18 tumors induced a systemic and tumor-specific cytotoxic T-lymphocyte response that was effective in the periphery as well as in the brain. 50, 56 Using this model, we demonstrated that GCV does not affect the antitumoral activity of G207 given in various dosages in established s.c. and intracerebral tumors. These results are in contrast to previous reports indicating that GCV administration significantly enhanced the antitumoral activity of hrR3, a replication-competent HSV-1 mutant, in the 9L rat brain tumor model. 45, 46 Possible differences may include the difference in tumor models, rodent species, viral replication, gap junction expression, or the strength of the antitumoral immune response caused by virus infection. MGH-1, a multimutated HSV-1 vector with the same mutation as G207, exhibited no therapeutic effect in the 9L tumor model with or without GCV administration. 36 The resistance of 9L cells to MGH-1 seemed to largely account for the lack of efficacy. It has also been shown that enhancement of the effect of GCV on hrR3-mediated killing was observed only in 9L cells, and not in various human colorectal cancer cells in culture or in nude mice. 47, 48 These findings and our results imply that GCV-mediated enhancement of the oncolytic activity of replicationcompetent HSV-1 may not be a universally observed effect, but may in fact be seen only under certain conditions.
It has been suggested that bystander cell killing in vitro correlates with the levels of GCV triphosphate accumulation in bystander cells and is dependent upon the percentage of HSV-tk-expressing cells, the GCV concentration, and the length of incubation. 23 In C57BL/6 mice bearing s.c. GL261 gliomas, GCV treatment significantly decreased tumor size when tumors were inoculated with an HSV-tk-expressing defective vector/R3616 (replication-competent HSV-1 deleted for the ␥34.5 gene) combination but not with R3616 alone. 12 This suggests that the amount and duration of HSV-tk expression after replication-competent HSV-1 infection may not be sufficient to cause bystander killing before the cell is killed directly by the virus. The present results with G207 in the N18 tumor model suggest that the potential antitumoral action of GCV through HSV-tk, whether via antitumoral immune responses or crossover of GCV triphosphate to bystander cells, can be balanced out by its inhibition of HSV-1 replication. It is noteworthy that two of five mice that showed tumor shrinkage in response to a single high-dose G207 inoculation exhibited regrowth of tumors after termination of the GCV administration, whereas recurrence was not seen in any of the G207 responders of the saline group. This is presumably due to early eradication of viable G207 by GCV administration, while, in the absence of GCV, infectious G207 could be isolated from s.c. N18 tumors 13 days after intraneoplastic inoculation. 56 This finding suggests that GCV administration may act adversely to G207 efficacy under virus replication-permissive conditions; conversely, this finding supports the usefulness of GCV as a safety feature for the G207 tumor therapy. It should be noted that, in view of our in vitro data, the potential may still remain for GCV to enhance the Figure 3 . Effect of GCV administration on the antitumoral activity of G207 on intracerebral N18 tumors in A/J mice. A/J mice received a stereotactic injection of N18 cells into the right frontal lobe and were inoculated 5 days later with G207 (1.5 ϫ 10 7 PFU) or mock-infected extract (mock) at the same coordinates. GCV (50 mg/kg) or saline was administered daily by i.p. injection for 7 consecutive days starting 8 days after tumor implantation. G207 treatment significantly prolonged the survival of the brain tumor-bearing animals (P Ͻ .01, mockϩsaline or mockϩGCV versus G207ϩsaline or G207ϩGCV, Wilcoxon test), but GCV administration caused no significant difference in survival in either saline-or G207-inoculated animals (Wilcoxon test).
antitumoral effect of G207 under conditions that limit viral replication.
In conclusion, the present findings suggest that GCV administration may not be beneficial to the efficacy of G207 tumor therapy under conditions that favor active viral replication, because the potential HSV-tk/GCVmediated enhancement of G207 oncolytic activity may be balanced out by the inhibitory action of GCV on viral replication.
